Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Background and purpose Cognitive impairment occurs in ≤30% of all stroke survivors. However, effective therapies aimed at preventing poststroke cognitive decline are lacking. We assessed the efficacy of a multidomain intervention on preventing cognitive decline after stroke. Methods In this randomized, observer-blind trial patients were recruited within 3 months after an acute stroke in 5 Austrian neurological centers. Patients were assigned to a 24-month lifestyle-based multidomain intervention or standard stroke care. Primary outcomes were the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and occurrence of cognitive decline in the composite scores of at least 2 of 5 cognitive domains at 24 months. Results A total of 101 patients were randomized into multi-intervention and 101 into standard care during June 2010 and November 2012. Of them, 76 patients in the intervention group and 83 in the control group were included in the final intention-to-treat analysis. At 24 months, 8 of 76 (10.5%) patients in the intervention group and 10 of 83 (12.0%) patients in the control group showed cognitive decline corresponding to a relative risk reduction of 0.874 (95% confidence interval, 0.364-2.098). The change in ADAS-cog from baseline to 24 months was not different either (median 0 [IQR, -1 to 2] in both groups; P=0.808). Conclusions This trial found no benefit of 24-month multidomain intervention with focus on improvement in lifestyle and vascular risk factors on the incidence of poststroke cognitive decline in comparison with standard stroke care. Studies with a larger sample size are needed. Clinical trial registration URL: http://clinicaltrials.gov. Unique identifier: NCT01109836.

Key findings

Why it matters

In this 24-month trial of 202 stroke patients, a multidomain lifestyle intervention did not reduce cognitive decline compared with standard stroke care. The study found no benefit of this intervention for preventing cognitive decline after stroke.

Study details

How this study scored 64/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 64 of 100.64 of 100 points earned36 not earned

Published in a peer-reviewed journal, and it is a randomised controlled trial.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Stroke)
Journal's citation record 3 / 4 Stroke: journal h-index 455 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 2 / 4 101 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 4 / 7 Cited 70 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.4 citations a year over 13 year(s) since 2015
Impact for its field and year 3 / 6 Cited 5.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 8 other studies in this library
Still being cited 1 / 4 Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Wolf‐Dieter Heiss: h-index 87 (OpenAlex, whole career)
Institution's track record 0 / 3 Finnish Institute for Health and Welfare: institution h-index 663 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 6 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 26374482)
Free to read 0 / 2 Behind a paywall — scores zero
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Matz, K., Teuschl, Y., Firlinger, B., Dachenhausen, A., Keindl, M., Seyfang, L., et al. (2015). Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke: Randomized Trial. Stroke. https://doi.org/10.1161/strokeaha.115.009992

Vancouver

Matz K, Teuschl Y, Firlinger B, Dachenhausen A, Keindl M, Seyfang L, et al. Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke: Randomized Trial. Stroke. 2015. doi:10.1161/strokeaha.115.009992. PMID: 26374482.

BibTeX

@article{matz2015-26374482,
  author  = {Matz, K. and Teuschl, Y. and Firlinger, B. and Dachenhausen, A. and Keindl, M. and Seyfang, L. and Tuomilehto, J. and Brainin, M. and others},
  title   = {{Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke: Randomized Trial}},
  journal = {Stroke},
  year    = {2015},
  doi     = {10.1161/strokeaha.115.009992},
  pmid    = {26374482},
  url     = {https://doi.org/10.1161/strokeaha.115.009992}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

8 studies in the alzhub library list this one in their references.

Related studies in Treatments

Also tagged “cognitive-function”

1,118 studies in the library carry the topic tag “cognitive-function”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,118 tagged studies.

Similar studies

More on Treatments

See all studies in Treatments →